XORTX Therapeutics (XRTX) Stock Skyrockets on Kidney Drug Deal – Key Facts & Outlook
XORTX Therapeutics shares surged up to 40% intraday Friday after announcing a $3 million deal to acquire Vectus Biosystems’ preclinical kidney fibrosis drug program. Trading volume hit 7 million shares, far above its daily average. The stock closed up 21% but remains down about 25% year-to-date. XORTX’s market cap stands near $4.5 million.
